Matthias Hackl

CEO at TAmiRNA

Speaker

Dr. Matthias Hackl is co-founder and CEO of TAmiRNA GmbH, a Vienna-based company specializing in transcriptomics, RNA biomarker discovery, and molecular diagnostics. He holds a Ph.D. in biotechnology and has over 15 years of experience in non-coding RNA research and its translational application.

Dr. Hackl is an expert in the discovery, validation, and regulatory implementation of circulating microRNA biomarkers using liquid biopsy approaches. He has led multiple programs from biomarker identification through clinical validation to regulated in vitro diagnostic (IVD) products. Under his leadership, TAmiRNA developed and CE-marked hepatomiR® in 2022, Europe’s first approved microRNA-based diagnostic test.

He also has extensive experience in applying RNA biomarkers to assess drug-induced toxicity and adverse events, supporting both preclinical safety studies and clinical pharmacovigilance. Dr. Hackl has co-authored more than 150 peer-reviewed publications and is dedicated to advancing RNA-based precision diagnostics and biomarker-driven drug development.